应交易所要求,美/港股行情延时15分钟展示,下载APP即可免费查看实时行情。
关闭
EXEL 伊克力西斯
盘后交易 02-28 17:43:40 EST
38.69
+1.04
+2.76%
盘后
38.95
+0.26
+0.67%
17:43 EST
最高
38.72
最低
37.62
成交量
371.88万
今开
37.96
昨收
37.65
日振幅
2.92%
总市值
108.29亿
流通市值
91.24亿
总股本
2.80亿
成交额
1.43亿
换手率
1.58%
流通股本
2.36亿
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
数据加载中...
北京优虎网络科技有限公司
资讯
新帖
简况
伊克力西斯盘中异动 股价大涨5.04%
市场透视 · 02-21
伊克力西斯盘中异动 股价大涨5.04%
伊克力西斯2024财年实现净利润5.21亿美元,同比增加150.48%
市场透视 · 02-15
伊克力西斯2024财年实现净利润5.21亿美元,同比增加150.48%
异动解读 | 分析师看好前景上调目标价 伊克力西斯盘中大涨5%
异动解读 · 02-13
异动解读 | 分析师看好前景上调目标价 伊克力西斯盘中大涨5%
伊克力西斯盘中异动 大幅上涨5.00%报34.44美元
市场透视 · 02-13
伊克力西斯盘中异动 大幅上涨5.00%报34.44美元
巴克莱:维持Exelixis(EXEL.US)评级,由持股观望调整至持股观望评级, 目标价由25.00美元调整至29.00美元。
金融界 · 02-13
巴克莱:维持Exelixis(EXEL.US)评级,由持股观望调整至持股观望评级, 目标价由25.00美元调整至29.00美元。
Piper Sandler:维持Exelixis(EXEL.US)评级,由增持调整至增持评级, 目标价由37.00美元调整至38.00美元。
金融界 · 02-12
Piper Sandler:维持Exelixis(EXEL.US)评级,由增持调整至增持评级, 目标价由37.00美元调整至38.00美元。
Exelixis公司第四季度调整后每股收益$0.55超出预期$0.43,销售额$5.6675亿超出预期$5.6342亿
财报速递 · 02-11
Exelixis公司第四季度调整后每股收益$0.55超出预期$0.43,销售额$5.6675亿超出预期$5.6342亿
Truist Securities:维持Exelixis(EXEL.US)评级,由买入调整至买入评级, 目标价由42.00美元调整至43.00美元。
金融界 · 01-27
Truist Securities:维持Exelixis(EXEL.US)评级,由买入调整至买入评级, 目标价由42.00美元调整至43.00美元。
Stephens & Co.:重申Exelixis(EXEL.US)评级,由持股观望调整至持股观望评级, 目标价由29.00美元调整至29.00美元。
金融界 · 01-27
Stephens & Co.:重申Exelixis(EXEL.US)评级,由持股观望调整至持股观望评级, 目标价由29.00美元调整至29.00美元。
HC Wainwright & Co.:重申Exelixis(EXEL.US)评级,由买入调整至买入评级, 目标价由40.00美元调整至40.00美元。
金融界 · 01-27
HC Wainwright & Co.:重申Exelixis(EXEL.US)评级,由买入调整至买入评级, 目标价由40.00美元调整至40.00美元。
大摩:上调Exelixis(EXEL.US)评级,由持股观望调整至增持评级, 目标价由30.00美元调整至40.00美元。
金融界 · 01-27
大摩:上调Exelixis(EXEL.US)评级,由持股观望调整至增持评级, 目标价由30.00美元调整至40.00美元。
伊克力西斯盘中异动 股价大跌5.22%
市场透视 · 01-24
伊克力西斯盘中异动 股价大跌5.22%
奥本海默:下调Exelixis(EXEL.US)评级,由优于大市调整至Perform评级, 目标价由41.00美元调整至33.00美元。
金融界 · 01-24
奥本海默:下调Exelixis(EXEL.US)评级,由优于大市调整至Perform评级, 目标价由41.00美元调整至33.00美元。
伊克力西斯盘中异动 快速下挫5.13%报34.56美元
市场透视 · 01-22
伊克力西斯盘中异动 快速下挫5.13%报34.56美元
奥本海默:维持Exelixis(EXEL.US)评级,由优于大市调整至优于大市评级, 目标价由38.00美元调整至41.00美元。
金融界 · 01-16
奥本海默:维持Exelixis(EXEL.US)评级,由优于大市调整至优于大市评级, 目标价由38.00美元调整至41.00美元。
Truist Securities:维持Exelixis(EXEL.US)评级,由买入调整至买入评级, 目标价由38.00美元调整至42.00美元。
金融界 · 01-15
Truist Securities:维持Exelixis(EXEL.US)评级,由买入调整至买入评级, 目标价由38.00美元调整至42.00美元。
摩根大通证券公司:维持Exelixis(EXEL.US)评级,由优于大市调整至优于大市评级, 目标价由34.00美元调整至41.00美元。
金融界 · 01-15
摩根大通证券公司:维持Exelixis(EXEL.US)评级,由优于大市调整至优于大市评级, 目标价由34.00美元调整至41.00美元。
Piper Sandler:维持Exelixis(EXEL.US)评级,由增持调整至增持评级, 目标价由36.00美元调整至37.00美元。
金融界 · 01-13
Piper Sandler:维持Exelixis(EXEL.US)评级,由增持调整至增持评级, 目标价由36.00美元调整至37.00美元。
HC Wainwright & Co.:维持Exelixis(EXEL.US)评级,由买入调整至买入评级, 目标价由29.00美元调整至40.00美元。
金融界 · 01-10
HC Wainwright & Co.:维持Exelixis(EXEL.US)评级,由买入调整至买入评级, 目标价由29.00美元调整至40.00美元。
Guggenheim:维持Exelixis(EXEL.US)评级,由买入调整至买入评级, 目标价由33.00美元调整至42.00美元。
金融界 · 01-07
Guggenheim:维持Exelixis(EXEL.US)评级,由买入调整至买入评级, 目标价由33.00美元调整至42.00美元。
加载更多
公司概况
公司名称:
伊克力西斯
所属市场:
NASDAQ
上市日期:
--
主营业务:
Exelixis, Inc.是一家生物科技公司,致力于研发癌症小分子治疗。公司于1994年11月在特拉华州注册为Exelixis制药股份有限公司,并于2000年2月改为Exelixis股份有限公司。公司的资源、研发、生产专注于COMETRIQ(卡博替尼胶囊,公司全资的多靶点受体酪氨酸激酶抑制剂)。公司目标是将COMETRIQ发展成一项主要的特许肿瘤经营产品,认为COMETRIQ治疗恶化、转移的MTC的批准给实现该目标、树立商业地位提供了一个机会。
发行价格:
--
{"stockData":{"symbol":"EXEL","market":"US","secType":"STK","nameCN":"伊克力西斯","latestPrice":38.69,"timestamp":1740776400000,"preClose":37.65,"halted":0,"volume":3718820,"hourTrading":{"tag":"盘后","latestPrice":38.95,"preClose":38.69,"latestTime":"17:43 EST","volume":180823,"amount":6996885.228472001,"timestamp":1740782590953},"delay":0,"floatShares":235818705,"shares":279881450,"eps":1.76,"marketStatus":"盘后交易","change":1.04,"latestTime":"02-28 17:43:40 EST","open":37.96,"high":38.72,"low":37.62,"amount":142705091.28792,"amplitude":0.029216,"askPrice":38.98,"askSize":1,"bidPrice":38.7,"bidSize":500,"shortable":3,"etf":0,"ttmEps":1.76,"tradingStatus":3,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1740790800000},"marketStatusCode":4,"adr":0,"adrRate":0,"listingDate":955425600000,"exchange":"NASDAQ","adjPreClose":37.65,"preHourTrading":{"tag":"盘前","latestPrice":37.68,"preClose":37.65,"latestTime":"09:29 EST","volume":992,"amount":37523.67273599999,"timestamp":1740752977597},"postHourTrading":{"tag":"盘后","latestPrice":38.95,"preClose":38.69,"latestTime":"17:43 EST","volume":180823,"amount":6996885.228472001,"timestamp":1740782590953},"volumeRatio":1.34022,"impliedVol":0.4106,"impliedVolPercentile":0.4343},"requestUrl":"/m/hq/s/EXEL","defaultTab":"news","newsList":[{"id":"2513911742","title":"伊克力西斯盘中异动 股价大涨5.04%","url":"https://stock-news.laohu8.com/highlight/detail?id=2513911742","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2513911742?lang=zh_cn&edition=full","pubTime":"2025-02-21 22:53","pubTimestamp":1740149583,"startTime":"0","endTime":"0","summary":"北京时间2025年02月21日22时53分,伊克力西斯股票出现波动,股价急速上涨5.04%。截至发稿,该股报36.86美元/股,成交量41.3734万股,换手率0.15%,振幅2.79%。机构评级方面,在所有23家参与评级的机构中,57%的券商给予买入建议,39%的券商给予持有建议,4%的券商给予卖出建议。伊克力西斯股票所在的生物技术行业中,整体涨幅为0.28%。伊克力西斯公司简介:Exelixis Inc是一家发现、研发并将癌症治疗方法商业化的生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250221225303a24eb5e6&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250221225303a24eb5e6&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4532","EXEL","BK4139"],"gpt_icon":0},{"id":"2511236670","title":"伊克力西斯2024财年实现净利润5.21亿美元,同比增加150.48%","url":"https://stock-news.laohu8.com/highlight/detail?id=2511236670","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2511236670?lang=zh_cn&edition=full","pubTime":"2025-02-16 00:00","pubTimestamp":1739635242,"startTime":"0","endTime":"0","summary":"2月16日,伊克力西斯公布财报,公告显示公司2024财年净利润为5.21亿美元,同比增加150.48%;其中营业收入为21.69亿美元,同比增加18.52%,每股基本收益为1.80美元。从资产负债表来看,伊克力西斯总负债7.43亿美元,其中短期债务25.01百万美元,资产负债比为4.03,流动比率为3.64。机构评级:截至2025年2月16日,当前有22家机构对伊克力西斯目标价做出预测,其中目标均价为37.00美元,其中最低目标价为23.00美元,最高目标价为45.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250216000048a247299f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250216000048a247299f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["EXEL"],"gpt_icon":0},{"id":"1199811140","title":"异动解读 | 分析师看好前景上调目标价 伊克力西斯盘中大涨5%","url":"https://stock-news.laohu8.com/highlight/detail?id=1199811140","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1199811140?lang=zh_cn&edition=full","pubTime":"2025-02-14 03:14","pubTimestamp":1739474073,"startTime":"0","endTime":"0","summary":"伊克力西斯(EXEL)周四盘中大涨5%,引发市场高度关注。\n\n消息方面,巴克莱重申对伊克力西斯评级为持股观望,但同时上调其目标价从25美元升至29美元。外资机构上调目标价,反映外界对该公司前景看好。\n\n分析人士表示,此举有望支撑伊克力西斯短期内股价表现,为公司的发展带来资金利好。不过公司未来能否持续获利,仍需观察其项目进展情况。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"异动解读 | 分析师看好前景上调目标价 伊克力西斯盘中大涨5%","news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["EXEL"],"gpt_icon":0},{"id":"2511579424","title":"伊克力西斯盘中异动 大幅上涨5.00%报34.44美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2511579424","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2511579424?lang=zh_cn&edition=full","pubTime":"2025-02-14 03:11","pubTimestamp":1739473888,"startTime":"0","endTime":"0","summary":"北京时间2025年02月14日03时11分,伊克力西斯股票出现异动,股价大幅上涨5.00%。截至发稿,该股报34.44美元/股,成交量194.72万股,换手率0.70%,振幅4.86%。最近的财报数据显示,该股实现营业收入21.69亿美元,净利润5.21亿美元,每股收益1.80美元,毛利20.92亿美元,市盈率19.56倍。机构评级方面,在所有23家参与评级的机构中,57%的券商给予买入建议,39%的券商给予持有建议,4%的券商给予卖出建议。伊克力西斯股票所在的生物技术行业中,整体涨幅为1.01%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250214031128a244e279&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250214031128a244e279&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","BK4532","EXEL"],"gpt_icon":0},{"id":"2511524526","title":"巴克莱:维持Exelixis(EXEL.US)评级,由持股观望调整至持股观望评级, 目标价由25.00美元调整至29.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2511524526","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2511524526?lang=zh_cn&edition=full","pubTime":"2025-02-13 23:42","pubTimestamp":1739461332,"startTime":"0","endTime":"0","summary":"巴克莱:维持Exelixis(EXEL.US)评级,由持股观望调整至持股观望评级, 目标价由25.00美元调整至29.00美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/02/13234248149779.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["EXEL"],"gpt_icon":0},{"id":"2510701123","title":"Piper Sandler:维持Exelixis(EXEL.US)评级,由增持调整至增持评级, 目标价由37.00美元调整至38.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2510701123","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2510701123?lang=zh_cn&edition=full","pubTime":"2025-02-12 22:32","pubTimestamp":1739370757,"startTime":"0","endTime":"0","summary":"Piper Sandler:维持Exelixis(EXEL.US)评级,由增持调整至增持评级, 目标价由37.00美元调整至38.00美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/02/12223248121874.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["EXEL"],"gpt_icon":0},{"id":"1113158480","title":"Exelixis公司第四季度调整后每股收益$0.55超出预期$0.43,销售额$5.6675亿超出预期$5.6342亿","url":"https://stock-news.laohu8.com/highlight/detail?id=1113158480","media":"财报速递","labels":["express"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1113158480?lang=zh_cn&edition=full","pubTime":"2025-02-12 05:12","pubTimestamp":1739308378,"startTime":"0","endTime":"0","summary":"Exelixis报告季度每股收益为$0.55,高于分析师一致预期的$0.43,超出27.91%。这一数据较去年同期的每股收益$0.33增长了66.67%。以上内容来自Benzinga Earnings专栏,原文如下:Exelixis reported quarterly earnings of $0.55 per share which beat the analyst consensus estimate of $0.43 by 27.91 percent. This is a 66.67 percent increase over earnings of $0.33 per share from the same period last year. The company reported quarterly sales of $566.75 million which beat the analyst consensus estimate of $563.42 million by 0.59 percent. This is a 18.16 percent increase","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Exelixis公司第四季度调整后每股收益$0.55超出预期$0.43,销售额$5.6675亿超出预期$5.6342亿","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EXEL"],"gpt_icon":0},{"id":"2506830219","title":"Truist Securities:维持Exelixis(EXEL.US)评级,由买入调整至买入评级, 目标价由42.00美元调整至43.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2506830219","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2506830219?lang=zh_cn&edition=full","pubTime":"2025-01-28 00:41","pubTimestamp":1737996075,"startTime":"0","endTime":"0","summary":"Truist Securities:维持Exelixis(EXEL.US)评级,由买入调整至买入评级, 目标价由42.00美元调整至43.00美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/01/28004147864325.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["EXEL"],"gpt_icon":0},{"id":"2506035203","title":"Stephens & Co.:重申Exelixis(EXEL.US)评级,由持股观望调整至持股观望评级, 目标价由29.00美元调整至29.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2506035203","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2506035203?lang=zh_cn&edition=full","pubTime":"2025-01-27 22:41","pubTimestamp":1737988903,"startTime":"0","endTime":"0","summary":"Stephens & Co.:重申Exelixis(EXEL.US)评级,由持股观望调整至持股观望评级, 目标价由29.00美元调整至29.00美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/01/27224147863497.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["EXEL"],"gpt_icon":0},{"id":"2506741193","title":"HC Wainwright & Co.:重申Exelixis(EXEL.US)评级,由买入调整至买入评级, 目标价由40.00美元调整至40.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2506741193","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2506741193?lang=zh_cn&edition=full","pubTime":"2025-01-27 21:04","pubTimestamp":1737983042,"startTime":"0","endTime":"0","summary":"HC Wainwright & Co.:重申Exelixis(EXEL.US)评级,由买入调整至买入评级, 目标价由40.00美元调整至40.00美元。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/01/27210447861282.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["EXEL"],"gpt_icon":0},{"id":"2506322004","title":"大摩:上调Exelixis(EXEL.US)评级,由持股观望调整至增持评级, 目标价由30.00美元调整至40.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2506322004","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2506322004?lang=zh_cn&edition=full","pubTime":"2025-01-27 18:22","pubTimestamp":1737973324,"startTime":"0","endTime":"0","summary":"大摩:上调Exelixis(EXEL.US)评级,由持股观望调整至增持评级, 目标价由30.00美元调整至40.00美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/01/27182247851022.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["EXEL"],"gpt_icon":0},{"id":"2505861371","title":"伊克力西斯盘中异动 股价大跌5.22%","url":"https://stock-news.laohu8.com/highlight/detail?id=2505861371","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2505861371?lang=zh_cn&edition=full","pubTime":"2025-01-24 22:40","pubTimestamp":1737729643,"startTime":"0","endTime":"0","summary":"北京时间2025年01月24日22时40分,伊克力西斯股票出现波动,股价大幅跳水5.22%。截至发稿,该股报32.35美元/股,成交量24.427万股,换手率0.09%,振幅3.63%。机构评级方面,在所有23家参与评级的机构中,52%的券商给予买入建议,39%的券商给予持有建议,9%的券商给予卖出建议。伊克力西斯股票所在的生物技术行业中,整体跌幅为0.10%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250124224045a22e5c6f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250124224045a22e5c6f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["EXEL","BK4532","BK4139"],"gpt_icon":0},{"id":"2505851949","title":"奥本海默:下调Exelixis(EXEL.US)评级,由优于大市调整至Perform评级, 目标价由41.00美元调整至33.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2505851949","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2505851949?lang=zh_cn&edition=full","pubTime":"2025-01-24 20:22","pubTimestamp":1737721341,"startTime":"0","endTime":"0","summary":"奥本海默:下调Exelixis(EXEL.US)评级,由优于大市调整至Perform评级, 目标价由41.00美元调整至33.00美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/01/24202247805340.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["EXEL"],"gpt_icon":0},{"id":"2505721823","title":"伊克力西斯盘中异动 快速下挫5.13%报34.56美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2505721823","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2505721823?lang=zh_cn&edition=full","pubTime":"2025-01-22 22:48","pubTimestamp":1737557292,"startTime":"0","endTime":"0","summary":"北京时间2025年01月22日22时48分,伊克力西斯股票出现异动,股价快速下挫5.13%。截至发稿,该股报34.56美元/股,成交量34.9635万股,换手率0.12%,振幅5.27%。最近的财报数据显示,该股实现营业收入5.40亿美元,净利润1.18亿美元,每股收益0.41美元,毛利5.22亿美元,市盈率22.43倍。机构评级方面,在所有23家参与评级的机构中,57%的券商给予买入建议,35%的券商给予持有建议,8%的券商给予卖出建议。伊克力西斯股票所在的生物技术行业中,整体涨幅为0.18%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250122224813986f7ae1&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250122224813986f7ae1&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","EXEL","BK4532"],"gpt_icon":0},{"id":"2504469069","title":"奥本海默:维持Exelixis(EXEL.US)评级,由优于大市调整至优于大市评级, 目标价由38.00美元调整至41.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2504469069","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2504469069?lang=zh_cn&edition=full","pubTime":"2025-01-17 02:13","pubTimestamp":1737051195,"startTime":"0","endTime":"0","summary":"奥本海默:维持Exelixis(EXEL.US)评级,由优于大市调整至优于大市评级, 目标价由38.00美元调整至41.00美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/01/17021347536202.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["EXEL"],"gpt_icon":0},{"id":"2503267456","title":"Truist Securities:维持Exelixis(EXEL.US)评级,由买入调整至买入评级, 目标价由38.00美元调整至42.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2503267456","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2503267456?lang=zh_cn&edition=full","pubTime":"2025-01-15 23:57","pubTimestamp":1736956659,"startTime":"0","endTime":"0","summary":"Truist Securities:维持Exelixis(EXEL.US)评级,由买入调整至买入评级, 目标价由38.00美元调整至42.00美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/01/15235747498066.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["EXEL"],"gpt_icon":0},{"id":"2503362679","title":"摩根大通证券公司:维持Exelixis(EXEL.US)评级,由优于大市调整至优于大市评级, 目标价由34.00美元调整至41.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2503362679","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2503362679?lang=zh_cn&edition=full","pubTime":"2025-01-15 23:48","pubTimestamp":1736956135,"startTime":"0","endTime":"0","summary":"摩根大通证券公司:维持Exelixis(EXEL.US)评级,由优于大市调整至优于大市评级, 目标价由34.00美元调整至41.00美元。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/01/15234847498027.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["EXEL","159848","399975"],"gpt_icon":0},{"id":"2503758165","title":"Piper Sandler:维持Exelixis(EXEL.US)评级,由增持调整至增持评级, 目标价由36.00美元调整至37.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2503758165","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2503758165?lang=zh_cn&edition=full","pubTime":"2025-01-13 23:31","pubTimestamp":1736782317,"startTime":"0","endTime":"0","summary":"Piper Sandler:维持Exelixis(EXEL.US)评级,由增持调整至增持评级, 目标价由36.00美元调整至37.00美元。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/01/13233147402838.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["EXEL"],"gpt_icon":0},{"id":"2502866840","title":"HC Wainwright & Co.:维持Exelixis(EXEL.US)评级,由买入调整至买入评级, 目标价由29.00美元调整至40.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2502866840","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2502866840?lang=zh_cn&edition=full","pubTime":"2025-01-10 21:27","pubTimestamp":1736515669,"startTime":"0","endTime":"0","summary":"HC Wainwright & Co.:维持Exelixis(EXEL.US)评级,由买入调整至买入评级, 目标价由29.00美元调整至40.00美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/01/10212747358712.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["EXEL"],"gpt_icon":0},{"id":"2501274787","title":"Guggenheim:维持Exelixis(EXEL.US)评级,由买入调整至买入评级, 目标价由33.00美元调整至42.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2501274787","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2501274787?lang=zh_cn&edition=full","pubTime":"2025-01-08 01:00","pubTimestamp":1736269251,"startTime":"0","endTime":"0","summary":"Guggenheim:维持Exelixis(EXEL.US)评级,由买入调整至买入评级, 目标价由33.00美元调整至42.00美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/01/08010047234056.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["EXEL"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.exelixis.com","stockEarnings":[{"period":"1week","weight":0.073},{"period":"1month","weight":0.1549},{"period":"3month","weight":0.0326},{"period":"6month","weight":0.4464},{"period":"1year","weight":0.7184},{"period":"ytd","weight":0.1306}],"compareEarnings":[{"period":"1week","weight":-0.0415},{"period":"1month","weight":-0.0322},{"period":"3month","weight":-0.029},{"period":"6month","weight":0.0379},{"period":"1year","weight":0.1556},{"period":"ytd","weight":-0.0018}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Exelixis, Inc.是一家生物科技公司,致力于研发癌症小分子治疗。公司于1994年11月在特拉华州注册为Exelixis制药股份有限公司,并于2000年2月改为Exelixis股份有限公司。公司的资源、研发、生产专注于COMETRIQ(卡博替尼胶囊,公司全资的多靶点受体酪氨酸激酶抑制剂)。公司目标是将COMETRIQ发展成一项主要的特许肿瘤经营产品,认为COMETRIQ治疗恶化、转移的MTC的批准给实现该目标、树立商业地位提供了一个机会。","yearOnYearQuotes":[{"month":1,"riseRate":0.52,"avgChangeRate":0.017784},{"month":2,"riseRate":0.48,"avgChangeRate":0.02002},{"month":3,"riseRate":0.541667,"avgChangeRate":-0.009275},{"month":4,"riseRate":0.541667,"avgChangeRate":0.053269},{"month":5,"riseRate":0.44,"avgChangeRate":-0.000424},{"month":6,"riseRate":0.56,"avgChangeRate":0.026357},{"month":7,"riseRate":0.56,"avgChangeRate":0.051069},{"month":8,"riseRate":0.44,"avgChangeRate":-0.011108},{"month":9,"riseRate":0.44,"avgChangeRate":-0.043067},{"month":10,"riseRate":0.56,"avgChangeRate":-0.003645},{"month":11,"riseRate":0.6,"avgChangeRate":0.059719},{"month":12,"riseRate":0.64,"avgChangeRate":0.054171}],"exchange":"NASDAQ","name":"伊克力西斯","nameEN":"Exelixis"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.31.3","shortVersion":"4.31.3","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"伊克力西斯(EXEL)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供伊克力西斯(EXEL)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"伊克力西斯,EXEL,伊克力西斯股票,伊克力西斯股票老虎,伊克力西斯股票老虎国际,伊克力西斯行情,伊克力西斯股票行情,伊克力西斯股价,伊克力西斯股市,伊克力西斯股票价格,伊克力西斯股票交易,伊克力西斯股票购买,伊克力西斯股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"伊克力西斯(EXEL)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供伊克力西斯(EXEL)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}